Patent · US Active

huTNFR1 selective antagonists

US9045535B2 · kind B2 · utility

1Cited by

1References

4Claims

0Family size

Assignee

UNIVERSITAT STUTTGART · DE

Inventors

Klaus Pfizenmaier · Tiefenbronn, DE
Peter Scheurich · Stuttgart, DE
Roland Kontermann · Jeffery Road, DE
Sabine Muenkel · Schrobenhausen, DE

Key dates

Filing date	Feb 13, 2013
Grant date	Jun 2, 2015
Priority date	—
Expiry date	May 19, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.